The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
Background: Camrelizumab (SHR1210) is a high-affinity, humanized immunoglobulin programmed cell death 1 (PD-1) monoclonal antibody. It was developed by Jiangsu Hengrui Medicine Co. Ltd. and has been approved for relapsed or refractory classical Hodgkin lymphoma patients and hepatocellular carcinoma...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
Frontiers Media S.A.,
2020-10-01T00:00:00Z.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
| Collocazione: |
A1234.567 |
|---|---|
| Copia 1 | Disponibile |